scispace - formally typeset
Open AccessJournal ArticleDOI

Characterization of Respiratory Drug Delivery with Enhanced Condensational Growth using an Individual Path Model of the Entire Tracheobronchial Airways

TLDR
Evaluating the delivery of inhaled pharmaceutical aerosols using an enhanced condensational growth (ECG) approach in an airway model extending from the oral cavity to the end of the tracheobronchial (TB) region indicated that targeting the region of TB deposition by controlling the inlet temperature conditions and initial aerosol size also appeared possible.
Abstract
The objective of this study was to evaluate the delivery of inhaled pharmaceutical aerosols using an enhanced condensational growth (ECG) approach in an airway model extending from the oral cavity to the end of the tracheobronchial (TB) region. The geometry consisted of an elliptical mouth-throat (MT) model, the upper TB airways extending to bifurcation B3, and a subsequent individual path model entering the right lower lobe of the lung. Submicrometer monodisperse aerosols with diameters of 560 and 900 nm were delivered to the mouth inlet under control (25 °C with subsaturated air) or ECG (39 or 42 °C with saturated air) conditions. Flow fields and droplet characteristics were simulated using a computational fluid dynamics model that was previously demonstrated to accurately predict aerosol size growth and deposition. Results indicated that both the control and ECG delivery cases produced very little deposition in the MT and upper TB model (approximately 1%). Under ECG delivery conditions, large size increases of the aerosol droplets were observed resulting in mass median aerodynamic diameters of 2.4–3.3 μm exiting B5. This increase in aerosol size produced an order of magnitude increase in aerosol deposition within the TB airways compared with the controls, with TB deposition efficiencies of approximately 32–46% for ECG conditions. Estimates of downstream pulmonary deposition indicted near full lung retention of the aerosol during ECG delivery. Furthermore, targeting the region of TB deposition by controlling the inlet temperature conditions and initial aerosol size also appeared possible.

read more

Content maybe subject to copyright    Report

Citations
More filters
Journal ArticleDOI

In Silico Models of Aerosol Delivery to the Respiratory Tract – Development and Applications

TL;DR: Recommendations are made on the need for more refined model validations, use of a concurrent experimental and CFD approach for developing aerosol delivery systems, and development of a stochastic individual path (SIP) model of aerosol transport and deposition throughout the respiratory tract.
Journal ArticleDOI

Comparing MDI and DPI Aerosol Deposition Using In Vitro Experiments and a New Stochastic Individual Path (SIP) Model of the Conducting Airways

TL;DR: The developed in silico model provides new insights into the lung delivery of pharmaceutical aerosols and can be applied in future studies in combination with pharmacokinetic analysis to establish bioequivalence between devices.
Journal ArticleDOI

In vitro tests for aerosol deposition. I: Scaling a physical model of the upper airways to predict drug deposition variation in normal humans.

TL;DR: A new in vitro test method is described to predict the median and range of aerosol drug deposition seen in vivo, consistent with 1:1 predictions of total lung deposition from a marketed powder inhaler in trained normal adults.
Journal ArticleDOI

Evaluation of the Respimat Soft Mist Inhaler using a Concurrent CFD and In Vitro Approach

TL;DR: Results of this study indicate that modifications to the current Respimat MP and control of specific patient variables may significantly reduce deposition in the device and may decrease high oropharyngeal drug loss observed in vivo.
References
More filters
Journal ArticleDOI

Mucus-penetrating nanoparticles for drug and gene delivery to mucosal tissues.

TL;DR: The tenacious mucus barrier properties that have precluded the efficient penetration of therapeutic particles are described and the design and development of new mucus-penetrating particles that may avoid rapid mucus clearance mechanisms are reviewed to provide targeted or sustained drug delivery for localized therapies in mucosal tissues.
Journal ArticleDOI

Nanoparticles for drug delivery to the lungs.

TL;DR: Novel methods formulating nanoparticles into the form of micron-scale dry powders have been developed, which exhibit improved handling and delivery, while releasing nanoparticles upon deposition in the lungs.
Journal ArticleDOI

Models of human lung airways and their application to inhaled particle deposition

TL;DR: In this paper, the authors developed a model of the human respiratory tract based on detailed morphometric measurements of a silicone rubber cast of the tracheobronchial airways, which contained geometrical parameters, including airway segment diameters, lengths, branching angles and angles of inclination to gravity.
Related Papers (5)